Literature DB >> 33252026

A practical approach to the management of cerebral amyloid angiopathy.

Mariel G Kozberg1,2,3, Valentina Perosa1,2,3,4, M Edip Gurol2,3, Susanne J van Veluw1,2,3.   

Abstract

Cerebral amyloid angiopathy is a common small vessel disease in the elderly involving vascular amyloid-β deposition. Cerebral amyloid angiopathy is one of the leading causes of intracerebral hemorrhage and a significant contributor to age-related cognitive decline. The awareness of a diagnosis of cerebral amyloid angiopathy is important in clinical practice as it impacts decisions to use lifelong anticoagulation or nonpharmacological alternatives to anticoagulation such as left atrial appendage closure in patients who have concurrent atrial fibrillation, another common condition in older adults. This review summarizes the latest literature regarding the management of patients with sporadic cerebral amyloid angiopathy, including diagnostic criteria, imaging biomarkers for cerebral amyloid angiopathy severity, and management strategies to decrease intracerebral hemorrhage risk. In a minority of patients, the presence of cerebral amyloid angiopathy triggers an autoimmune inflammatory reaction, referred to as cerebral amyloid angiopathy-related inflammation, which is often responsive to immunosuppressive treatment in the acute phase. Diagnosis and management of cerebral amyloid angiopathy-related inflammation will be presented separately. While there are currently no effective therapeutics available to cure or halt the progression of cerebral amyloid angiopathy, we discuss emerging avenues for potential future interventions.

Entities:  

Keywords:  Cerebral amyloid angiopathy; cortical superficial siderosis; intracerebral hemorrhage; microbleeds; microinfarcts; small vessel disease

Mesh:

Year:  2020        PMID: 33252026      PMCID: PMC9097498          DOI: 10.1177/1747493020974464

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   6.948


  132 in total

Review 1.  Cerebral microinfarcts: the invisible lesions.

Authors:  Eric E Smith; Julie A Schneider; Joanna M Wardlaw; Steven M Greenberg
Journal:  Lancet Neurol       Date:  2012-03       Impact factor: 44.182

2.  Prospective Study of Fasting Blood Glucose and Intracerebral Hemorrhagic Risk.

Authors:  Cheng Jin; Guohong Li; Kathryn M Rexrode; Mahmut E Gurol; Xiaodong Yuan; Ying Hui; Chunyu Ruan; Anand Vaidya; Yanxiu Wang; Shouling Wu; Xiang Gao
Journal:  Stroke       Date:  2017-12-11       Impact factor: 7.914

Review 3.  Ischemic brain injury in cerebral amyloid angiopathy.

Authors:  Yael D Reijmer; Susanne J van Veluw; Steven M Greenberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

4.  Two types of sporadic cerebral amyloid angiopathy.

Authors:  Dietmar Rudolf Thal; Estifanos Ghebremedhin; Udo Rüb; Haruyasu Yamaguchi; Kelly Del Tredici; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

5.  Risk factors for intracerebral hemorrhage in a pooled prospective study.

Authors:  Jared D Sturgeon; Aaron R Folsom; W T Longstreth; Eyal Shahar; Wayne D Rosamond; Mary Cushman
Journal:  Stroke       Date:  2007-08-30       Impact factor: 7.914

6.  Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.

Authors:  Vivek Y Reddy; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Jonathan L Halperin; David Holmes
Journal:  Circulation       Date:  2013-01-16       Impact factor: 29.690

Review 7.  Management of intracerebral hemorrhage.

Authors:  Mahmut Edip Gurol; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

8.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Authors:  Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann
Journal:  Heart Rhythm       Date:  2017-05-31       Impact factor: 6.343

9.  Different microvascular alterations underlie microbleeds and microinfarcts.

Authors:  Susanne J van Veluw; Ashley A Scherlek; Whitney M Freeze; Annemieke Ter Telgte; Andre J van der Kouwe; Brian J Bacskai; Matthew P Frosch; Steven M Greenberg
Journal:  Ann Neurol       Date:  2019-06-14       Impact factor: 10.422

10.  Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Authors:  S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

View more
  3 in total

Review 1.  Neuropathology of Vascular Brain Health: Insights From Ex Vivo Magnetic Resonance Imaging-Histopathology Studies in Cerebral Small Vessel Disease.

Authors:  Susanne J van Veluw; Konstantinos Arfanakis; Julie A Schneider
Journal:  Stroke       Date:  2022-01-10       Impact factor: 7.914

Review 2.  Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management.

Authors:  Maria Clara Zanon Zotin; Lukas Sveikata; Anand Viswanathan; Pinar Yilmaz
Journal:  Curr Opin Neurol       Date:  2021-04-01       Impact factor: 6.283

3.  Human Galectin-7 Gene LGALS7 Promoter Sequence Polymorphisms and Risk of Spontaneous Intracerebral Hemorrhage: A Prospective Study.

Authors:  Ming-Dong Wang; Jing Tian; John H Zhang; Shun-Ying Zhao; Ming-Jing Song; Zhan-Xiang Wang
Journal:  Front Mol Neurosci       Date:  2022-03-23       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.